Potential Plasma Biomarkers for Diagnosis of Alzheimer’s Disease: An Overview

سال انتشار: 1403
محل انتشار: فصلنامه پیشرفت درتحقیقات بیوشیمی و شیمی، دوره: 7، شماره: 2
کد COI اختصاصی: JR_PCBR-7-2_001
زبان مقاله: انگلیسی
تعداد مشاهده: 18

نویسندگان

Department of Biotechnology, School of Life Sciences, Swami Ramanand Teerth Marathwada University, Nanded ۴۳۱۶۰۶, India

چکیده

Alzheimer’s disease (AD) is the widely known neuro-degenerative disease, responsible for cognitive decline and progressive memory loss, results from the brain shrinkage (called atrophy) and degradation of neurons of brain, globally almost ۶۰-۷۰% people are suffering from it and most prevalent amongst older peoples of above ۴۰ years. The major or marker symptoms symptom of this disease is dementia, impairment of thinking, and changes in behavioral pattern. The disease progression commences with short memory loss to severe memory impairment. To cope with this, prior disease diagnosis helps in the prevention and treatment of diseases, as there is no complete treatment and cure available to this disease. Once the patients have been diagnosed with this disease, there are several pharmacological or non-pharmacological treatments can be given. Up to now, the technique available for the AD detection is CSF and PET scan which are painful and expensive. Several blood or plasma biomarkers can be used to detect the progression or prevalence of the diseases, based on non-invasive blood-based biomarker and it is cost-effective technique and with similar efficiency in comparison to classical one.In this investigation, we focus on potential biological markers for the investigation and AD detection. The blood biomarkers can be useful are Plasma GFAP has been found to be the most potential blood biomarker. There is no any standard procedure/test been accepted to be used for the AD diagnosis as a blood biomarker. The other biomarkers can be used along with Plasma GFAP are level of TGF-β۱ in plasma and Activity NO synthase in Leukocytes, plasma gelsolin (GSN) and matrix metalloproteinase ۳ (MMP۳), plasma Cystatin C, and High-Density Lipoprotein.

کلیدواژه ها

Alzheimer’s disease, Biological Markers, Plasma GFAP, CSF, PET

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.